Abstract
Objective
To investigate systematically the role of systemic corticosteroid therapy in non-arteritic anterior ischemic optic neuropathy (NA-AION).
Methods
The study consists of a cohort of 613 consecutive patients (696 eyes), first seen in our clinic from 1973 to 2000. Of this cohort, 312 patients (364 eyes) voluntarily opted for systemic steroid therapy, and 301 (332 eyes) for no treatment. At first visit, all patients in both groups had a detailed ophthalmic and medical history, and comprehensive ophthalmic evaluation. Visual evaluation was done by recording Snellen visual acuity, and visual fields with a Goldmann perimeter. The same ophthalmic evaluation was performed at each follow-up visit. Patients in the steroid-treated group were initially given 80 mg Prednisone daily for 2 weeks, and then tapered down to 70 mg for 5 days, 60 mg for 5 days, and then cutting down by 5 mg every 5 days. Visual outcome in the two groups was compared
Results
Median follow-up was 3.8 years. At 6 months from onset of NA-AION, of the eyes with initial visual acuity 20/70 or worse and seen within 2 weeks of onset, there was visual acuity improvement in 69.8% (95% confidence interval (CI): 57.3%, 79.9%) in the treated group, compared to 40.5% (95% CI: 29.2%, 52.9%) in the untreated group (odds ratio of improvement: 3.39; 95% CI:1.62, 7.11; p = 0.001). Comparison of visual field defect at 6 months from onset of NA-AION, among those seen within 2 weeks of NA-AION onset with moderate to severe initial visual field defect, there was improvement in 40.1% (95% CI: 33.1%, 47.5%) of the treated group, and 24.5% (95% CI: 17.7%, 32.9%) of the untreated group (odds ratio: 2.06, 95% CI: 1.24, 3.40; p = 0.005). In both treated and untreated groups, the visual acuity and visual fields kept improving up to about 6 months from onset of NA-AION, and very little thereafter.
Conclusion
This study suggested that NA-AION eyes treated during the acute phase with systemic corticosteroids resulted in a significantly higher probability of improvement in visual acuity (p = 0.001) and visual field (p = 0.005) than in the untreated group. Both visual acuity and visual fields improved up to 6 months after onset of NA-AION.
Similar content being viewed by others
References
Beck RW, Hayreh SS, Podhajsky PA, Tan E-S, Moke PS (1997) Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 123:212–217
Beck RW, Servais GE, Hayreh SS (1987) Anterior ischemic optic neuropathy IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 94:1503–1508
Beri M, Klugman MR, Kohler JA, Hayreh SS (1987) Anterior ischemic optic neuropathy VII. Incidence of bilaterality and various influencing factors. Ophthalmology 94:1020–1028
Dai J, Buijs R, Swaab D (2004) Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer’s disease. Br J Pharmacol 143:606–610
Esterman B (1968) Grid for scoring visual fields. II. Perimeter. Arch Ophthalmol 79:400–406
Foulds WS (1969) Visual disturbances in systemic disorders: optic neuropathy and systemic disease. Trans Ophthalmol Soc UK 89:125–146
Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86:247–248
Hayreh SS (1969) Blood supply of the optic nerve head and its role in optic atrophy, glaucoma and oedema of the optic disc. Br J Ophthalmol 53:721–748
Hayreh SS (1972) Optic disc vasculitis. Br J Ophthalmol 56:652–670
Hayreh SS (1974) Pathogenesis of cupping of the optic disc. Br J Ophthalmol 58:863–876
Hayreh SS (1974) Anterior ischaemic optic neuropathy III. Treatment, prophylaxis, and differential diagnosis. Br J Ophthalmol 58:98l–989
Hayreh SS (1977) Optic disc edema in raised intracranial pressure V. Pathogenesis. Arch Ophthalmol 95:1553–1565
Hayreh SS (1978) Fluids in the anterior part of the optic nerve in health and disease. Surv Ophthalmol 23:1–25
Hayreh SS (1990) Anterior ischaemic optic neuropathy: Differentiation of arteritic from non-arteritic type and its management. Eye 4:25–41
Hayreh SS (2001) The blood supply of the optic nerve head and the evaluation of it - Myth and reality. Prog Retin Eye Res 20:563–593
Hayreh SS (2003) Management of central retinal vein occlusion. Ophthalmologica 217:167–188
Hayreh SS (2004) Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye 18:1188–1206
Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24:493–519
Hayreh SS (2008) Intravitreal triamcinolone for non-arteritic anterior ischemic optic neuropathy. J Neuroophthalmol 28:77–78
Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES (1990) Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion: a 10-year prospective study. Graefes Arch Clin Exp Ophthalmol 228:281–296
Hayreh SS, Massanari RM, Yamada T, Hayreh SMS (1981) Experimental allergic encephalomyelitis I. Optic nerve and central nervous system manifestations.. Invest Ophthalmol Vis Sci 21:256–269
Hayreh SS, Podhajsky PA, Raman R, Zimmerman B (1997) Giant cell arteritis: Validity and reliability of various diagnostic criteria. Am J Ophthalmol 123:285–296
Hayreh SS, Podhajsky PA, Zimmerman B (1997) Non-arteritic anterior ischemic optic neuropathy - Time of onset of visual loss. Am J Ophthalmol 124:641–647
Hayreh SS, Podhajsky PA, Zimmerman B (1999) Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 213:76–96
Hayreh SS, Zimmerman B (2003) Management of giant cell arteritis. Ophthalmologica 217:239–259
Hayreh SS, Zimmerman B (2005) Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: Their pattern and prevalence at the initial presentation. Arch Ophthalmol 123:1554–1562
Hayreh SS, Zimmerman MB (2007) Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 245:1107–1121
Hayreh SS, Zimmerman B (2008) Non-arteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 115:298–305
Hayreh SS, Zimmerman B, Kardon RH (2002) Visual improvement with corticosteroid therapy in giant cell arteritis: Report of a large study and review of literature. Acta Ophthalmol Scand 80:355–367
Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL (1994) Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 117:603–624
Ischemic Optic Neuropathy Decompression Trial Research Group (2000) Ischemic optic neuropathy decompression trial: twenty-four-month update. Arch Ophthalmol 118:793–798
Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:782–783
Jonas JB, Söfker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427
Jonas JB, Spandau UH, Harder B, Saunder G (2007) Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 245:749–750
Kaderli B, Avci R, Yucel A, Guler K, Gelisken O (2007) Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 27:164–168
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927
McLeod D, Marshall J, Kohner EM (1980) Role of axoplasmic transport in the pathophysiology of ischaemic disc swelling. Br J Ophthalmol 64:247–261
Miller GR, Smith JL (1966) Ischemic optic neuropathy. Am J Ophthalmol 62:103–115
Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K Ischemic Optic Neuropathy Decompression Trial Research Group (2002) The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 134:317–328
The Ischemic Optic Neuropathy Decompression Trial Research Group (1995) Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 273:625–632
Acknowledgements
We are extremely grateful to Drs. Randy H. Kardon, H. Stanley Thompson and Michael Wall, and Mrs. Patricia Podhajsky for their invaluable help with the visual field evaluation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grant EY-1151 from the National Institutes of Health, Bethesda, Maryland, and in part by unrestricted grant from Research to Prevent Blindness, Inc., New York.
Rights and permissions
About this article
Cite this article
Hayreh, S.S., Zimmerman, M.B. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246, 1029–1046 (2008). https://doi.org/10.1007/s00417-008-0805-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-008-0805-8